Morgan Stanley Zynerba Pharmaceuticals, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.33 - $1.39 $2,914 - $12,275	-8,831 Reduced 20.25%	34,783 $44,000
Q1 2023 May 15, 2023	SELL	$0.4 - $0.67 $1,602 - $2,683	-4,005 Reduced 8.41%	43,614 $18,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $0.72 $6,315 - $9,093	12,630 Added 36.1%	47,619 $25,000
Q3 2022 Nov 14, 2022	SELL	$0.87 - $1.36 $1,105 - $1,728	-1,271 Reduced 3.51%	34,989 $25,000
Q2 2022 Oct 27, 2022	SELL	$0.86 - $2.06 $513 - $1,229	-597 Reduced 1.62%	36,260 $41,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $2.06 $513 - $1,229	-597 Reduced 1.62%	36,260 $41,000
Q1 2022 Oct 27, 2022	BUY	$1.83 - $3.02 $1,092 - $1,802	597 Added 1.65%	36,857 $75,000
Q1 2022 May 13, 2022	SELL	$1.83 - $3.02 $113,352 - $187,061	-61,941 Reduced 62.69%	36,857 $75,000
Q4 2021 Feb 14, 2022	SELL	$2.88 - $4.3 $24,808 - $37,040	-8,614 Reduced 8.02%	98,798 $284,000
Q3 2021 Nov 15, 2021	BUY	$3.72 - $5.35 $399,572 - $574,654	107,412 New	107,412 $456,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.